• 1
    United States Bureau of the Census: Statistical abstract of the United States. 112th edition. Washington DC, United States Government Printing Office, 1992
  • 2
    Physicians' Desk Reference, 47th edition. Montvale, NJ, Medical Economics Data, 1993
  • 3
    KelleyWN, HarrisEDJr, RuddyS, SledgeCB, editors: Textbook of Rheumatology. Fourth edition. Philadelphia, WB Saunders, 1993
  • 4
    McCartyDJ, KoopmanWJ, editors: Arthritis and Allied Conditions. Twelfth edition. Philadelphia, Lea & Febiger, 1993
  • 5
    Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch D: Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 18: 188194, 1991
  • 6
    Fries JF, Spitz PW, Williams CA, Bloch DA, Singh G, Hubert HB: A toxicity index for comparison of side effects among different drugs. Arthritis Rheum 33: 121130, 1990
  • 7
    Fries JF: The ARAMIS (American Rheumatism Association Medical Information System) post-marketing surveillance program. Drug Info J 19: 257262, 1985
  • 8
    WyngaardenJB, SmithLH, BennettJC, editors: Cecil Textbook of Medicine. Philadelphia, WB Saunders, 1992
  • 9
    WilsonJD, BraunwaldE, IsselbacherKJ, PetersdorfRG, MartinJB, FauciAS, RootRK, editors: Harrison's Principles of Internal Medicine. Twelfth edition. New York, McGraw-Hill, 1991
  • 10
    Borg G, Allander E, Goobar JE: Disease-modifying antirheumatic drug therapy: an expensive therapy despite inexpensive drugs. Scand J Rheumatol 19: 115121, 1990
  • 11
    Liang MH, Fries JF: Containing costs in chronic disease: monitoring strategies in the gold therapy of rheumatoid arthritis. J Rheumatol 5: 241244, 1978
  • 12
    Gladen HE: Computer modeling antibiotic therapy costs. Drugs 35 (suppl 2): 208213, 1988
  • 13
    Schulman KA, Kinosiam B, Jacobson TA, Glick H, Willian MK, Koffer H, Eisenberg JM: Reducing high blood cholesterol level with drugs: cost-effectiveness of pharmacologic management. JAMA 264: 30253033, 1990